|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,582 GBX | -0.52% |
|
-2.85% | +9.12% |
| Apr. 17 | GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix | MT |
| Apr. 17 | GSK: positive clinical results for gonorrhea | CF |
July 31 (Reuters) - Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.
The doses would be manufactured in European countries including France, Belgium, Germany and Italy.
Sanofi is leading the clinical development of the vaccine and expects to launch a pivotal trial by the end of this year. (Reporting By Deena Beasley; editing by Grant McCool)
| 1st Jan change | Capi. | |
|---|---|---|
| +9.12% | 80.88B | |
| +28.51% | 676B | |
| +23.85% | 554B | |
| -8.27% | 349B | |
| +14.63% | 318B | |
| +6.45% | 291B | |
| +2.88% | 210B | |
| -0.46% | 204B | |
| -9.90% | 194B | |
| -11.83% | 144B |
GSK PLC 
